BACE1 and Alzheimer disease: Therefore, our results suggest that monotherapeutic approaches targeting BACE1 may not be sufficient to block a detrimental feed-forward link between neprilysin reduction, increased levels of Aβ plaque formation and BACE1 elevation during the course of AD progression.